Browse Studies — Arctuva

Phase 1

Safety and Efficacy of Expanded KIR-HLA Mismatched Natural Killer Cell Immunotherapy (AdaptNK) for High-Risk Myeloid Diseases as Bridge to Allogeneic Hematopoietic Stem Cell Transplantation

This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 …

Relapsed Adult AMLRefractory AMLAcute Myelogenous Leukemia

Estimated

~$10 – $6,250

Masonic Cancer Center, University of MinnesotaNCT07591649

Observational

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, sympto…

Relapsed Adult AMLPrimary Refractory Acute Myeloid LeukemiaHigh Risk Acute Myeloid Leukemia

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT05237258

Phase 1

A Phase 1 Study of Oral PCLX-001 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.

Relapsed Adult AML

Estimated

~$10 – $8,750

Pacylex PharmaceuticalsNCT06613217

Phase 1

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed …

Leukemia, Myeloid, AcuteRefractory AMLRelapsed Adult AML+2 more

Estimated

~$10 – $8,750

Aptose Biosciences Inc.NCT03850574